Amica Kurniati Ko

Amica Kurniati Ko

Auto-generated profile, based on publicly available information

Amica Kurniati Ko

Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
AKAmica K. Ko
Amica K. Ko
LMLaura Milana
Laura Milana
NRNicoletta Riva
Nicoletta Riva
LBLorenza Bertu
Lorenza Bertu
LBLaurent Bertoletti
Laurent Bertoletti
MLMandy N. Lauw
Mandy N. Lauw
Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism, but relatively common in patients with myeloproliferative neoplasms (MPN). Studies on management and outcomes for patients with MPN-SVT, including comparisons with non-MPN-SVT, are scarce. We assessed anticoagulant management and recurrent thrombosis, bleeding and survival outcomes in SVT patients with and without MPN. We conducted a multicenter comparative cohort study in adults with SVT using individual patient-data from three published studies and two hospital cohorts. Anticoagulant management after SVT diagnosis was evaluated. 6-months cumulative incidences of recurrent thrombosis, bleeding and death were calculated. We used propensity-score weighting to compare outcomes between patients with and without MPN. A subanalysis excluding patients with cirrhosis or solid cancer was performed. We investigated 1189 SVT patients, 187 with underlying MPN. Anticoagulation was started in 76.1% of patients within 30 days after SVT diagnosis, 78.6% were still anticoagulated at 6 months; this was similar between patients with and without MPN. 6-month cumulative incidence of recurrent thrombosis and bleeding was 2.5% and 4.5%, respectively. Overall survival was 93.7% at 6-months follow-up. No significant differences were observed in clinical outcomes between patients with and without MPN, also confirmed by subanalyses. In this large cohort, incidences of recurrent thrombosis, bleeding and survival 6 months after SVT were similar in patients with and without MPN. This suggests that MPN-related SVT could be regarded similarly to non-cirrhotic, non-malignant SVT for anticoagulant management and outcomes. Prospective studies with long-term follow-up are still needed for MPN-related SVT patients.

13 November 2026 in Blood Advances
Verified
Journal Article
Closed access
DTDouglas Tremblay
Douglas Tremblay
AKAmica Ko
Amica Ko
PCPavlina Chrysafi
Pavlina Chrysafi
JHJoan How
Joan How
RZRebecca Zon
Rebecca Zon
MLMandy N. Lauw
Mandy N. Lauw
Patients with myeloproliferative neoplasms (MPN) are at risk of splanchnic vein thrombosis (SVT). Previous studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but they are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of patients with MPN-SVT from the international GASTRO-MPN consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of whom 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/transjugular intrahepatic portosystemic shunt thrombosis, and 138 (18%) had a thrombosis recurrence outside the splanchnic bed (74% were venous). In addition, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, previous thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.89; P = .01). This was driven by a lower risk of SVT extension/recurrence (HR, 0.62; 95% CI, 0.42-0.90; P = .01) but not by extra-splanchnic thrombosis recurrence (HR, 0.97; 95% CI, 0.72-1.30; P = .82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n = 275), cytoreductive therapy was associated with an HR of 0.65 (95% CI, 0.40-1.07; P = .09) for recurrent thrombosis. These data support the use of cytoreductive therapy for patients with MPN-SVT to prevent recurrent thrombosis, particularly SVT extension/recurrence.

14 July 2026 in HemaSphere
Verified
Journal Article
Open access
AKAmica K. Ko
Amica K. Ko
PMPim Mutsaers
Pim Mutsaers
LKLukas M. van Kleij
Lukas M. van Kleij
AVAmária Vledder
Amária Vledder
EPElise R. A. Pennings
Elise R. A. Pennings
MLMandy N. Lauw
Mandy N. Lauw
Chimeric antigen receptor (CAR) T‐cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B‐cell lymphoma (R/R LBCL). Although thrombosis and bleeding complications have been increasingly reported, their clinical relevance and risk factors remain unclear, also due to heterogeneity between reporting studies. We investigated the incidence of thrombosis and bleeding in a more homogeneous real‐world multicenter cohort by analyzing 250 adults with R/R LBCL who were included in the Dutch “Follow that CAR!” multicenter registry, and all received axicabtagene ciloleucel (axi‐cel) CAR T‐cell therapy. We assessed the impact of thrombosis and bleeding, incorporated as time‐dependent covariates on overall survival and explored associations with cytokine release syndrome (CRS), immune effector cell‐associated neurotoxicity syndrome (ICANS), anticoagulant therapy, and laboratory parameters. One‐year cumulative incidences of thrombosis and bleeding were 6.3% and 11.0%, respectively. Median time to thrombosis or bleeding was 28 days after infusion for both events. Bleeding was associated with poorer overall survival (hazard ratio [HR] 3.77, 95% CI 1.96–7.27). Patients with a CAR‐HEMATOTOX score ≥2 before CAR T‐cell therapy (HR 3.62, 95% CI 1.23–10.69), therapeutic anticoagulation at time of infusion (HR 3.74, 95% CI 1.33–10.49), or thrombocytopenia grade ≥3 (platelet count < 50 × 10 9 /L) at time of infusion (HR 3.55, 95% CI 1.12–11.26, P = 0.03) had a significantly higher risk of bleeding. Our study confirms the high risk and clinical relevance of bleeding in patients receiving CAR T‐cell therapy. Prospective studies are necessary to confirm these results and to guide recommendations regarding modifiable risk factors such as the use of anticoagulation or transfusion thresholds during CAR T‐cell therapy.

21 October 2026 in Blood Advances
Verified
Journal Article
Open access
DTDouglas Tremblay
Douglas Tremblay
AKAmica Kurniati Ko
Amica Kurniati Ko
PCPavlina Chrysafi
Pavlina Chrysafi
JHJoan How
Joan How
LKLisa Baumann Kreuziger
Lisa Baumann Kreuziger
MLMandy N. Lauw
Mandy N. Lauw